Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported first-quarter total revenue of $19.4 million, driven by $4.8 million in net product sales from the initial U.S. launch of MYQORZO and an $11.9 million milestone payment from Bayer. Management highlighted strong early commercial traction with over 275 prescribers and approximately 680 patients treated in the first partial quarter, alongside positive Phase 3 results for ACACIA-HCM showing aficamten improved symptoms and exercise performance in non-obstructive HCM.
Key figures
- Revenue
- 19400000
- Drug Name
- MYQORZO (aficamten)
- Guidance
- GAAP Combined R&D and SG&A Expense $830 million to $870 million
- Phase Of Trial
- Phase 3
- Net loss
- $206.0 million
- Cash burn
- $144 million
- Rd expenses
- $95.5 million
- Sga expenses
- $104.9 million
- Cash position
- $1.1 billion
- Product revenue
- $4.8 million
- Milestone revenue
- $11.9 million
- Collaboration revenue
- $2.6 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.